Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients General Outcomes and Prognostic Factors From the SAMURAI Register
Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients General Outcomes and Prognostic Factors From the SAMURAI Register
复制标题
DOI：
10.1161/strokeaha.109.562991
复制
发表时间：
2009-11-01
期刊：
影响因子：
8.3
通讯作者：
Minematsu, Kazuo
中科院分区：
文献类型：
--
作者：
Toyoda, Kazunori;Koga, Masatoshi;Minematsu, Kazuo
背景和目的--一项回顾性、多中心、观察性研究记录了低剂量静脉注射重组组织型纤溶酶原激活剂治疗患者的临床结局，并确定了结局预测因素（0.6 mg/kg阿替普酶），2005年在日本获批，方法-在10个日本卒中中心接受重组组织型纤溶酶原激活剂治疗的连续性卒中患者。结果-共研究了600例患者（377例男性，72 ± 12岁）。美国国立卫生研究院卒中量表评分中位数从重组组织型纤溶酶原激活剂前的13分降至24小时后的8分。23例患者在36小时内出现症状性脑出血，与基线国立卫生研究院卒中量表评分相比增加≥ 1分（3.8%; 95% CI，2.6%-5.7%）。3个月时，43例患者死亡（7.2%; 5.4%-9.5%），199例患者（33.2%; 29.5%-37.0%）有改良兰金量表评分
Background and Purpose - A retrospective, multicenter, observational study was conducted to document clinical outcomes and to identify outcome predictors in patients treated with low-dose intravenous recombinant tissue plasminogen activator (0.6 mg/kg alteplase), which was approved in Japan in 2005, within 3 hours of stroke onset.Methods - Consecutive patients with stroke treated with recombinant tissue plasminogen activator in 10 Japanese stroke centers were included.Results - A total of 600 patients (377 men, 72 +/- 12 years old) were studied. Median National Institutes of Health Stroke Scale scores decreased from 13 before recombinant tissue plasminogen activator to 8 at 24 hours later. Symptomatic intracerebral hemorrhage within 36 hours with a >= 1-point increase from the baseline National Institutes of Health Stroke Scale score developed in 23 patients (3.8%; 95% CI, 2.6% to 5.7%). At 3 months, 43 patients had died (7.2%; 5.4% to 9.5%), and 199 patients (33.2%; 29.5% to 37.0%) had a modified Rankin Scale score